Literature DB >> 19132221

The 'PAI-1 paradox' in vascular remodeling.

Isabel Diebold1, Damir Kraicun, Steve Bonello, Agnes Görlach.   

Abstract

Vascular remodelling is a complex phenomenon associated with restructuring of the vessel wall as a consequence of disruption of vascular homeostasis. Alterations of the vascular wall have been linked to a variety of cardiovascular disorders including atherosclerosis, vascular injury and pulmonary hypertension. Plasminogen activator inhibitor-1 (PAI-1) is a member of the serpin (serine proteinase inhibitor) family and acts as an important inhibitor of fibrinolysis by interfering with the plasminogen system. In addition to its anti-fibrinolytic effects, PAI-1 appears to modulate cellular responses linked to vascular remodelling. Since PAI-1 levels have been shown to be altered in various disorders associated with vascular remodelling of the systemic and pulmonary vascular bed, this serpin may play a pivotal role in the pathogenesis of these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19132221

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  32 in total

1.  Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  New Horiz Transl Med       Date:  2014-09-01

2.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

3.  Plasminogen activator inhibitor-1 is associated with leukocyte telomere length in American Indians: findings from the Strong Heart Family Study.

Authors:  H Peng; F Yeh; J Lin; L G Best; S A Cole; E T Lee; B V Howard; J Zhao
Journal:  J Thromb Haemost       Date:  2017-05-03       Impact factor: 5.824

Review 4.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 5.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

6.  A new method for in vivo visualization of vessel remodeling using a near-infrared dye.

Authors:  Marie Billaud; Jeremy A Ross; Mark A Greyson; Anthony C Bruce; Scott A Seaman; Katherine R Heberlein; Jenny Han; Angela K Best; Shayn M Peirce; Brant E Isakson
Journal:  Microcirculation       Date:  2011-04       Impact factor: 2.628

7.  Evaluation of various endothelial biomarkers in ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Didem L Kozaci; Yasar Yildiz; Safak Bilge; Isil Coker; Sergir Maltas; Necati Gunay; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

8.  Coagulation and Fibrinolytic System Protein Profiles in Women with Normal Pregnancies and Pregnancies Complicated by Hypertension.

Authors:  Sarah A Hale; Burton Sobel; Anna Benvenuto; Adrienne Schonberg; Gary J Badger; Ira M Bernstein
Journal:  Pregnancy Hypertens       Date:  2012-04-01       Impact factor: 2.899

Review 9.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

10.  Circulating levels of inflammatory markers in intrauterine growth restriction.

Authors:  Theodora Boutsikou; George Mastorakos; Marialena Kyriakakou; Alexandra Margeli; Demetrios Hassiakos; Ioannis Papassotiriou; Christina Kanaka-Gantenbein; Ariadne Malamitsi-Puchner
Journal:  Mediators Inflamm       Date:  2010-06-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.